Impact of improved access to medications for opioid use disorder in residential treatment
Addiction · 02.11.2026
DOI: 10.1111/add.70630 ↗Kurz gefasst
Fachartikel in der Zeitschrift Addiction, online erschienen am 02.11.2026. Verfasst von Mathieu Castry und 5 weiteren Autor:innen. Beteiligte Einrichtung: Boston Medical Center, Section of Infectious Diseases, Boston, MA, USA. Die Arbeit nennt 51 Literaturangaben. Gefördert von: NIDA NIH HHS, NIH HHS, National Institutes of Health.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Background and aim Health officials in the United States (USA) are seeking strategies to mitigate overdose mortality. Medications for opioid use disorder (MOUD) are effective but underused in residential treatment centers. We used a simulation model to investigate population‐level health and health economic impacts of requiring residential treatment centers to offer MOUD to patients with opioid use disorder (OUD). Design, setting and participants We used a cohort state‐transition model in Massachusetts, USA, simulating 4 strategies: (1) status quo – a small fraction of residential centers offers MOUD; (2) ‘Improved MOUD’ – all residential centers routinely offer MOUD to admitted patients; (3) ‘Improved MOUD with linkage’ – adding linkage to outpatient MOUD for those discharged on MOUD; and (4) ‘Improved MOUD with extended linkage’ – adding linkage for all patients being discharged. We used two complementary simulation approaches: a closed cohort estimating per‐person outcomes for residential treatment patients and an open cohort estimating state‐level impacts across the Massachusetts OUD population.
Measurements
Outcomes included person‐time on MOUD, overdose fatalities, costs (2024 US dollars), cost‐effectiveness and budgetary impact.
Results
In the closed cohort, compared with the status quo, the ‘Improved MOUD’ strategy increased person‐time in MOUD by 36% and prevented 5 [95% uncertainty interval (UI) = 1–6] overdose deaths per 10 000 individuals at one year. Over a lifetime horizon, this strategy extended life expectancy by 0.0041 life‐years (LY) and discounted quality‐adjusted life expectancy by 0.0034 quality‐adjusted life‐years (QALY) at an incremental lifetime cost per person of $309. ‘Improved MOUD with extended linkage’ was the preferred strategy, providing more LY (0.0096) and QALY (0.0080) at lower incremental cost ($198). The incremental cost‐effectiveness ratio compared with the status quo was $40 195/QALY gained. At the state level, this strategy prevented 2.64 (95% UI = 0.49–4.76) overdose deaths per 10 000 individuals over 10 years (a 0.40% reduction). The 5‐year budgetary impact to the Massachusetts health care system of providing MOUD in residential treatment was $9.65 million. Findings were robust in sensitivity analyses; however, there is some risk of unintended consequences should facilities choose to close rather than offer MOUD. In a scenario in which 21% of sites closed (reflecting centers that discourage MOUD) outcomes were worse than under the status quo. Summary Residential treatment programs for opioid use disorder appear to be an effective and cost‐effective venue for expanding the use of medications for opioid use disorder, with the greatest value achieved when care navigation links patients to community‐based treatment upon discharge.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Boston Medical Center, Section of Infectious Diseases, Boston, MA, USA.
- Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV and HIV (CHERISH), New York, NY, USA.
- Health Economics, Hospital Management and Nursing Research Department, School of Public Health, Université Libre de Bruxelles, Brussels, Belgium.
- University of Colorado School of Medicine, Divisions of Infectious Diseases and General Internal Medicine, Aurora, CO, USA.
- Department of Epidemiology, University of Colorado School of Public Health, Aurora, CO, USA.
- Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA.
ORCID-Profile: Mathieu Castry, Joshua Barocas, Zachary F Meisel, Benjamin P Linas
Förderung
- NIDA NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Castry, M., Zwick, H., Barocas, J., Meisel, Z. F., Walley, A. Y., & Linas, B. P. (2026). Impact of improved access to medications for opioid use disorder in residential treatment. Addiction. https://doi.org/10.1111/add.70630
Vancouver
Castry M, Zwick H, Barocas J, Meisel ZF, Walley AY, Linas BP. Impact of improved access to medications for opioid use disorder in residential treatment. Addiction. 2026. doi:10.1111/add.70630
BibTeX
@article{Castry2026,
author = {Castry, Mathieu and Zwick, Hana and Barocas, Joshua and Meisel, Zachary F and Walley, Alexander Y and Linas, Benjamin P},
title = {Impact of improved access to medications for opioid use disorder in residential treatment},
journal = {Addiction},
year = {2026},
doi = {10.1111/add.70630}
}
EUVIMED